Potassium Citrate and Citric Acid Oral Solution USP

Manufacturer
PAI Holdings, LLC dba PAI Pharma | PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma
Effective date
2024-11-19
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
6
Source
full-release
Hydrated at
2026-05-31 21:17:42

Label at a glance#

ProductPotassium Citrate and Citric Acid
Active ingredientPOTASSIUM CITRATE, CITRIC ACID MONOHYDRATE
Label structure14 sections

Indications and uses

Potassium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. In addition, it is a valuable adjuvant when administered with uricosuric agen...

Dosage and administration

Potassium Citrate and Citric Acid Oral Solution USP should be taken diluted in water according to directions, followed by additional water, if desired. Palatability is enhanced if chilled before taking. 3 to 6 teaspoonfuls (15 to 30 mL), diluted with 1 glass of water, after meals and at bedtime, or as directed by a physician. 1 to 3 teaspoonfuls (5 to 15 mL), diluted with 1/2 glass of water, after meals and at bed...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx ONLY

DESCRIPTION

DESCRIPTION SECTION

Potassium Citrate and Citric Acid Oral Solution USP is a stable and pleasant-tasting oral systemic alkalizer containing potassium citrate and citric acid in a sugar-free, non-alcoholic base.

Potassium Citrate and Citric Acid Oral Solution USP contains in each teaspoonful (5 mL):

POTASSIUM CITRATE           Monohydrate  1100 mg

CITRIC ACID                           Monohydrate  334 mg

Each mL contains 2 mEq potassium ion and is equivalent to 2 mEq bicarbonate (HCO 3).

Inactive Ingredients: FD&C Red No. 40, flavoring, polyethylene glycol, propylene glycol, purified water, sodium benzoate, and sorbitol solution.

ACTIONS

MECHANISM OF ACTION SECTION

Potassium citrate is absorbed and metabolized to potassium bicarbonate, thus acting as a systemic alkalizer. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of the potassium citrate is excreted in the urine unchanged.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Potassium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. This product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting and tolerable, even when administered for long periods. Potassium citrate does not neutralize the gastric juice or disturb digestion.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Severe renal impairment with oliguria or azotemia, untreated Addison's disease, adynamia episodica hereditaria, acute dehydration, heat cramps, anuria, severe myocardial damage, and hyperkalemia from any cause.

WARNINGS

WARNINGS SECTION

Large doses may cause hyperkalemia and alkalosis, especially in the presence of renal disease. Concurrent administration of potassium-containing medication, potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or cardiac glycosides may lead to toxicity.

PRECAUTIONS

PRECAUTIONS SECTION

Should be used with caution by patients with low urinary output unless under the supervision of a physician. As with all liquids containing a high concentration of potassium, patients should be directed to dilute adequately with water to minimize the possibility of gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations; and preferably, to take each dose after meals to avoid saline laxative effect.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Potassium Citrate and Citric Acid Oral Solution USP is generally well tolerated without any unpleasant side effects when given in recommended doses to patients with normal renal function and urinary output. However, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of hyperkalemia or alkalosis. Potassium intoxication causes listlessness, weakness, mental confusion, tingling of extremities, and other symptoms associated with a high concentration of potassium in the serum. Periodic determinations of serum electrolytes should be carried out in those patients with renal disease in order to avoid these complications. Hyperkalemia may exhibit the following electrocardiographic abnormalities: Disappearance of the P wave, widening and slurring of QRS complex, changes of the S-T segment, tall peaked T waves, etc.

To report SUSPECTED ADVERSE REACTIONS, contact Pharmaceutical Associates, Inc. at 1-800-845-8210 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

OVERDOSAGE SECTION

The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, hyperkalemia can result (see Contraindications and Warnings). Hyperkalemia, when detected, must be treated immediately because lethal levels can be reached in a few hours.

TREATMENT OF HYPERKALEMIA

SPL UNCLASSIFIED SECTION

Should hyperkalemia occur, treatment measures include the following: (1) Elimination of foods or medications containing potassium. (2) The intravenous administration of 300 to 500 mL/hr of dextrose solution (10 to 25%), containing 10 units of insulin/20 gm dextrose. (3) The use of exchange resins, hemodialysis, or peritoneal dialysis. In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the plasma potassium concentration can produce digitalis toxicity.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Potassium Citrate and Citric Acid Oral Solution USP should be taken diluted in water according to directions, followed by additional water, if desired. Palatability is enhanced if chilled before taking.

Usual Adult Dose

SPL UNCLASSIFIED SECTION

3 to 6 teaspoonfuls (15 to 30 mL), diluted with 1 glass of water, after meals and at bedtime, or as directed by a physician.

Usual Pediatric Dose

SPL UNCLASSIFIED SECTION

1 to 3 teaspoonfuls (5 to 15 mL), diluted with 1/2 glass of water, after meals and at bedtime, or as directed by a physician.

Usual Dosage Range

SPL UNCLASSIFIED SECTION

2 to 3 teaspoonfuls (10 to 15 mL), diluted with a glassful of water, taken four times a day. Potassium Citrate and Citric Acid Oral Solution USP, diluted with a glassful of water, taken four times a day will usually maintain a urinary pH of 7.0-7.6 throughout most of the 24 hours without unpleasant side effects. To check urinary pH, HYDRION Paper (pH 6.0-8.0) or NITRAZINE Paper (pH 4.5-7.5) are available and easy to use.

HOW SUPPLIED

HOW SUPPLIED SECTION

Potassium Citrate and Citric Acid Oral Solution USP (clear pink to red colored; berry-citrus flavored) is supplied in the following oral dosage form:

NDC 0121-0676-16: 16 fl oz (473 mL) bottle

STORAGE

STORAGE AND HANDLING SECTION

Keep tightly closed. Store at controlled room temperature, 20°-25°C (68°-77°F). Protect from excessive heat and freezing.

MANUFACTURED BY

SPL UNCLASSIFIED SECTION

Pharmaceutical Associates, Inc.

 Greenville, SC 29605
www.paipharma.com

R02/22

PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0121-0676-16

Potassium Citrate and Citric Acid Oral Solution USP
1100 mg/334 mg per 5 mL

A SUGAR-FREE SYSTEMIC ALKALIZER

Each teaspoonful (5 mL) contains:
Potassium Citrate Monohydrate…..1100 mg
Citric Acid Monohydrate…..334 mg

Each mL contains 2 mEq Potassium Ion, and is
equivalent to 2 mEq Bicarbonate (HCO3).

Rx ONLY

16 fl oz (473 mL)

Pharmaceutical Associates, Inc.
Greenville, SC 29605

INDICATIONS AND USAGE:  Potassium
Citrate and Citric Acid Oral Solution USP
is a stable and pleasant-tasting oral
systemic alkalizer. It is effective for long-
term maintenance of an alkaline urine,
especially when the administration of
sodium salts is undesirable or contra-
indicated.

See package insert for complete prescribing information.

X0676160317         R03/17

DOSAGE AND ADMINISTRATION:

Usual Adult Dosage:  3 to 6 teaspoonfuls
(15 to 30 mL) DILUTED with 1 glass of
water, after meals and at bedtime, or as
directed by a physician.

Usual Pediatric Dosage:  1 to 3 teaspoonfuls
(5 to 15 mL) DILUTED with 1 /2 glass of
water, after meals and at bedtime, or as
directed by a physician.

SHAKE WELL BEFORE USING.

STORAGE:  Keep tightly closed. Store at
controlled room temperature. 20° -25° C
(68° -77° F). Protect from excessive heat or
freezing.

Dispense in a tight, light-resistance container
with a child-resistant closure.

473 mL Bottle Label473 mL Bottle Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
309318citric acid 334 MG / potassium citrate 1100 MG in 5 mL Oral SolutionPSN6
309318citric acid 66.8 MG/ML / potassium citrate 220 MG/ML Oral SolutionSCD6
309318citric acid 334 MG / potassium citrate 1100 MG per 5 ML Oral SolutionSY6
309318Citric Acid 66.8 MG/ML / K+ citrate 220 MG/ML Oral SolutionSY6
309318Citric Acid 66.8 MG/ML / Pot citrate 220 MG/ML Oral SolutionSY6

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
ANHYDROUS CITRIC ACID Pharmacologic Class Indexing3Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
ce6d5c06-3ae0-18a6-d5b3-8cd3cc0f8906Product name720210625

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0121-0676-16Potassium Citrate and Citric Acid473 mL in 1 BOTTLESOLUTION4736

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0121-0676POTASSIUM CITRATE AND CITRIC ACID (POTASSIUM CITRATE AND CITRIC ACID MONOHYDRATE) SOLUTION [PAI HOLDINGS, LLC DBA PAI PHARMA]6Current NDC, Legacy NDC, 1 package rows20241121_ce42122f-8087-471f-b0a3-5524bdbd4526.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0121-0676-16ML - Milliliter0121-067694c817d6-748b-4708-ad4e-991f733c58ed12014-12-01

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
Citric Acid MonohydrateACTIVE INGREDIENT2968PHW8QP1
Potassium CitrateACTIVE INGREDIENTEE90ONI6FF1
Anhydrous Citric AcidACTIVE MOIETYXF417D3PSL1
FD&C Red No. 40INACTIVE INGREDIENTWZB9127XOA1
Polyethylene Glycol 400INACTIVE INGREDIENTB697894SGQ1
Propylene GlycolINACTIVE INGREDIENT6DC9Q167V31
Sodium BenzoateINACTIVE INGREDIENTOJ245FE5EU1
SorbitolINACTIVE INGREDIENT506T60A25R1
WaterINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0121-06760121-0676-16

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML · Source PDF

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 10 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
Sodium BenzoateSODIUM BENZOATEOJ245FE5EUSOLUTION / ORAL660 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
SorbitolSORBITOL506T60A25RSOLUTION / ORAL29268 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
FD&C Red No. 40FD&C RED NO. 40WZB9127XOASOLUTION / ORAL38 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
Polyethylene Glycol 400POLYETHYLENE GLYCOL 400B697894SGQSOLUTION / ORAL70200 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
SorbitolSORBITOL506T60A25RSOLUTION / ORAL29268 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
FD&C Red No. 40FD&C RED NO. 40WZB9127XOASOLUTION / ORAL38 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
Polyethylene Glycol 400POLYETHYLENE GLYCOL 400B697894SGQSOLUTION / ORAL70200 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
Sodium BenzoateSODIUM BENZOATEOJ245FE5EUSOLUTION / ORAL660 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
Propylene GlycolPROPYLENE GLYCOL6DC9Q167V3SOLUTION / ORAL22602 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
Propylene GlycolPROPYLENE GLYCOL6DC9Q167V3SOLUTION / ORAL22602 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Potassium Citrate and Citric AcidPOTASSIUM CITRATE AND CITRIC ACID MONOHYDRATEPAI Holdings, LLC dba PAI Pharmace42122f-8087-471f-b0a3-5524bdbd45262024-11-19Warnings, Adverse reactionsExact identifier
ndc (package): 0121-0676-16
ndc (product): 0121-0676
ndc11 (package): 00121067616
spl id: a89c03e3-61a9-46df-9de7-e73f522f123d
spl set id: ce42122f-8087-471f-b0a3-5524bdbd4526

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.